What is the equity of Medincell this year?
Medincell has equity of -42.29 M EUR this year.
Medincell Equity 2024
Medincell Equity
-42.29 M EUR
Medincell Dividend yield
Ticker
MEDCL.PA
ISIN
FR0004065605
WKN
A2N6VA
In 2024, Medincell's equity was -42.29 M EUR, a 216.31% increase from the -13.37 M EUR equity in the previous year.
Medincell Aktienanalyse
What does Medincell do?
Medincell SA is a leading biotechnology company based in Montpellier, France, specializing in the development and manufacturing of innovative drugs based on its proprietary Intellisome® technology platform. The company was founded in 1999 by Dr. Christophe Douat and has since built an impressive portfolio of products and services. Medincell's business model is based on the development and manufacturing of extended-release drugs through the integration of drugs into the Intellisome® technology platform. This is a novel concept based on the use of polymers that are capable of controlling and slowing down the release of drugs. This allows medications to be administered in a specific dosage and duration, providing greater effectiveness and tolerability for the patient. Medincell has several business areas, including the development of drugs for the treatment of central nervous system (CNS) disorders, including schizophrenia, depression, and chronic pain. The company is also working on the development of drugs for the treatment of infectious diseases and cancer, as well as the development of new technologies for drug manufacturing. Medincell's products include a range of drugs, including Long-Acting Risperidone (a depot preparation for the treatment of schizophrenia), Long-Acting Cabergoline (for the treatment of Parkinson's), and Long-Acting Naltrexone (for the treatment of alcohol and drug addiction). The company also has partnerships with other pharmaceutical companies such as Pierre Fabre, Sanofi, Janssen, and Pfizer for the development of products based on its Intellisome® technology platform. Another important area of Medincell is its service for drug development based on the Intellisome® technology platform. The company offers customers comprehensive support in the development, manufacturing, and approval of extended-release drugs. Customers can choose from a wide range of services, ranging from the identification of active ingredients to the implementation of clinical trials. Overall, Medincell has achieved impressive success in the launch of its products and services based on the Intellisome® technology platform. The company has won several awards for its innovative products and services in the pharmaceutical industry, including the Innovation Award from the European Society of Clinical Microbiology and Infectious Diseases in 2018 and the Excellence in Specialty Pharmaceuticals Award from BioPharm America in 2019. In summary, Medincell SA is a leading company in the biotechnology industry specializing in the development and manufacturing of extended-release drugs based on its Intellisome® technology platform. With an impressive range of products and services and partnerships with several renowned pharmaceutical companies, the company has a promising future as a key player in the pharmaceutical industry. Medincell ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Medincell's Equity
Medincell's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Medincell's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Medincell's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Medincell's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Medincell’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Medincell Stock
What was the equity of Medincell compared to the previous year?
The equity of Medincell has increased/decreased by 216.31% increased compared to the previous year.
What impact does a high equity have on investors of Medincell?
A high equity is advantageous for investors of Medincell as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Medincell?
A low equity can be a risk for investors of Medincell, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Medincell affect the company?
An increase in equity of Medincell can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Medincell affect the company?
A reduction in equity of Medincell can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Medincell?
Some factors that can affect the equity of Medincell include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Medincell so important for investors?
The equity of Medincell is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Medincell take to change the equity?
To change equity, Medincell can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Medincell pay?
Over the past 12 months, Medincell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medincell is expected to pay a dividend of 0 EUR.
What is the dividend yield of Medincell?
The current dividend yield of Medincell is .
When does Medincell pay dividends?
Medincell pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Medincell?
Medincell paid dividends every year for the past 0 years.
What is the dividend of Medincell?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Medincell located?
Medincell is assigned to the 'Health' sector.
Wann musste ich die Aktien von Medincell kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Medincell from 5/17/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/17/2024.
When did Medincell pay the last dividend?
The last dividend was paid out on 5/17/2024.
What was the dividend of Medincell in the year 2023?
In the year 2023, Medincell distributed 0 EUR as dividends.
In which currency does Medincell pay out the dividend?
The dividends of Medincell are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Medincell stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Medincell
Our stock analysis for Medincell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medincell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
